Evidence map›Paper›PMID 32851589›Full record

ArticleMolecular and cellular biochemistry2021

Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS-reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction.

Padmini Rajendran, Uma Maheshwari, Arun Muthukrishnan, Razia Muthuswamy, Krishnan Anand, Balasubramani Ravindran, Premnath Dhanaraj, Balasubramaninan Balamuralikrishnan, Soon Woong Chang, Woo Jin Chung

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. International journal of molecular sciences · 2026
    Article
  7. Cancer management and research · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Padmini RajendranDepartment of Biotechnology, Mother Teresa Women's University, Kodaikanal, Tamil Nadu, India.
Uma MaheshwariDepartment of Biotechnology, Mother Teresa Women's University, Kodaikanal, Tamil Nadu, India.
Arun MuthukrishnanDepartment of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India.
Razia MuthuswamyDepartment of Biotechnology, Mother Teresa Women's University, Kodaikanal, Tamil Nadu, India. razia581@gmail.com.
Krishnan AnandDepartment of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa. organicanand@gmail.com.ORCID http://orcid.org/0000-0002-8886-8482
Balasubramani RavindranDepartment of Environmental Energy Engineering, Kyonggi University, Suwon, South Korea.
Premnath DhanarajDepartment of Biotechnology, School of Agriculture and Biosciences, Karunya Institute of Technology and Science, Karunya Nagar, Coimbatore, 641114, India.
Balasubramaninan BalamuralikrishnanDepartment of Food Science and Biotechnology, Sejong University, Seoul, South Korea.
Soon Woong ChangDepartment of Environmental Energy Engineering, Kyonggi University, Suwon, South Korea.
Woo Jin ChungDepartment of Environmental Energy Engineering, Kyonggi University, Suwon, South Korea.
Kyonggi University · KRMother Teresa Women's University · INBharathiar University · INKarunya University · INNational Health Laboratory Service · ZASejong University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myricetin is categorized under the secondary metabolite flavonoid which includes a diverse range of consumable plant parts, and it has a potential against several classes of cancer including cancers and tumors. In the present study, the anticancer potential of the unique flavonoid-myricetin in A549 lung cancer cells was evaluated. Among different doses of myricetin, 73 μg/ml was more effective to prevent the cancer cell growth. It also promoted sub-G1 phase aggregation of cells and a equivalent decrease in the fraction of cells entering the S and subsequent phase which indicates apoptotic cell death. Myricetin generated enormous free radicals and, altered the potential of mitochondrial membrane in A549 cells as paralleled to untreated cells. In addition, myricetin treatment intensified the expression of P53 and relegated the expression of EGFR in A549 cells. These results suggested that myricetin exhibits cytotoxic potential by arresting the progression of cell cycle and ROS-dependent mitochondria-mediated mortality in cancer A549 lung cancer cells and it would be useful to develop as a drug candidate for lung cancer therapeutics. In silico experiments were carried out against human EGFR and P53 tumor suppressor protein to gain more insights into the binding mode of the myricetin may act as significant potential for anticancer therapy.

Indexed as

Oxidative StressReactive Oxygen SpeciesA549 CellsAntineoplastic AgentsApoptosisCell CycleCell Cycle CheckpointsCell ProliferationComputer SimulationDNA FragmentationErbB ReceptorsFlavonoidsFree RadicalsHumansInhibitory Concentration 50LigandsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsFlavonoidsFree RadicalsLigandsmyricetinReactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53A549 cellsApoptosisEGFRMMPMolecular dockingMyricetinP53 activation

Identifiers

PMID32851589
OpenAlexW3081079928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.